玻璃体腔连续雷珠单抗端口给药系统对比每月雷珠单抗治疗糖尿病黄斑水肿:Pagoda随机临床试验
这项3期多中心非劣效性随机临床试验纳入634例未治疗的中心累及型糖尿病黄斑水肿患者,比较端口给药系统每24周补充雷珠单抗100 mg/mL与每月雷珠单抗0.5 mg的疗效与安全性。第60和64周平均最佳矫正视力变化分别为9.6个字母与9.4个字母(差异0.2;95%CI -1.2至1.6),达到非劣效性界值-4.5个字母。端口给药系统组特别关注的不良事件更常见(27.5% vs 8.9%),但未报告眼内炎或视网膜脱离。
要点
- 端口给药系统每24周补充雷珠单抗100 mg/mL在64周内视力获益不劣于每月雷珠单抗0.5 mg。
- 第60和64周平均最佳矫正视力变化:端口给药系统组9.6个字母 vs 每月雷珠单抗组9.4个字母(差异0.2;95%CI -1.2至1.6)。
- 端口给药系统组特别关注的不良事件发生率27.5%(88例)高于每月雷珠单抗组8.9%(28例),未报告眼内炎或视网膜脱离。
核心结论
- 端口给药系统每24周补充雷珠单抗100 mg/mL组第60和64周平均最佳矫正视力变化与每月雷珠单抗0.5 mg组相当。
- 端口给药系统组特别关注的不良事件更常见,但未报告眼内炎或视网膜脱离。
- 雷珠单抗100 mg/mL经端口给药系统已于2025年2月在美国获批用于糖尿病黄斑水肿患者,提供有效、持久且总体耐受良好的治疗,至少64周内每6个月补充一次。
研究设计与样本
- 3期、多中心、非劣效性随机临床试验,在美国87个中心开展。
- 纳入至少18岁、未治疗的中心累及型糖尿病黄斑水肿患者,入组时间2019年9月30日至2021年6月25日,数据分析时间2019年9月30日至2022年9月19日。
- 参与者按3:2随机接受4次每月雷珠单抗0.5 mg后转为端口给药系统每24周补充雷珠单抗100 mg/mL,或接受每月雷珠单抗0.5 mg。
- 共634例参与者随机分组(端口给药系统组n=381;每月雷珠单抗组n=253),基线平均(SD)年龄60.7(9.6)岁,男性363例(57.3%),女性271例(42.7%)。
主要发现
- 第60和64周平均最佳矫正视力较基线变化:端口给药系统组增加9.6个字母 vs 每月雷珠单抗组增加9.4个字母(差异0.2;95%CI -1.2至1.6),达到非劣效性界值-4.5个字母。
- 端口给药系统组在植入后4周平均(SD)最佳矫正视力下降6.7(12.0)个字母,植入后16周平均最佳矫正视力与每月雷珠单抗组相似。
- 特别关注的不良事件:端口给药系统组88例(27.5%) vs 每月雷珠单抗组28例(8.9%)。
- 端口给药系统组未报告眼内炎或视网膜脱离病例。
关键数值与推荐
- 主要终点为第60和64周平均最佳矫正视力较基线变化,非劣效性界值为-4.5个字母。
- 端口给药系统每24周补充雷珠单抗100 mg/mL;每月雷珠单抗0.5 mg每4周一次。
临床怎么用
- 雷珠单抗100 mg/mL经端口给药系统已于2025年2月在美国获批用于糖尿病黄斑水肿患者,至少64周内每6个月补充一次。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Frequent visits and intravitreal anti-vascular endothelial growth factor (VEGF) injections are often required to manage diabetic macular edema (DME), burdening patients and their health care networks. The Port Delivery System (PDS) with ranibizumab is the first continuous anti-VEGF therapy that has the potential to reduce visit and treatment burden without sacrificing vision outcomes for patients with DME. OBJECTIVE: To evaluate the efficacy and safety through 64 weeks of ranibizumab, 100 mg/mL, via PDS with refill exchanges every 24 weeks (PDS Q24W) in patients with DME vs intravitreal injections of ranibizumab, 0.5 mg, every 4 weeks (monthly ranibizumab). DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was a phase 3, multicenter, noninferiority trial conducted across 87 sites in the US. Treatment-naïve patients at least 18 years old with center-involved DME were eligible for study participation. Enrollment was from September 30, 2019, to June 25, 2021; data were analyzed from September 30, 2019, to September 19, 2022. INTERVENTION: Participants were randomized 3:2 to receive 4 monthly doses of ranibizumab, 0.5 mg, followed by ranibizumab, 100 mg/mL, via PDS Q24W or monthly ranibizumab. MAIN OUTCOME AND MEASURE: The primary end point was change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 60 and 64. RESULTS: A total of 634 participants were randomized (PDS Q24W group, n = 381; monthly ranibizumab, n = 253). The mean (SD) age at baseline was 60.7 (9.6) years; 363 (57.3%) participants were male and 271 (42.7%) female. Adjusted mean BCVA change from baseline averaged over weeks 60 and 64 was an increase of 9.6 letters for PDS Q24W and 9.4 letters for monthly ranibizumab (difference, 0.2; 95% CI, -1.2 to 1.6), meeting the primary end point of PDS noninferiority (margin, -4.5 letters). PDS Q24W participants had a mean (SD) decrease of 6.7 (12.0) letters 4 weeks after PDS insertion; mean BCVA was similar to monthly ranibizumab 16 weeks after implantation. Adverse events of special interest were more common in the PDS Q24W group (88 participants; 27.5%) than the monthly ranibizumab group (28 participants; 8.9%). No cases of endophthalmitis or retinal detachment were reported with PDS Q24W. CONCLUSIONS AND RELEVANCE: This trial found that changes in BCVA from baseline averaged over weeks 60/64 in the PDS Q24W group were comparable to the monthly ranibizumab group. While AESIs were more common with PDS Q24W, there were no instances of endophthalmitis or retinal detachment. Continuous ranibizumab, 100 mg/mL, via PDS was approved in the US for patients with DME in February 2025 and provides effective, durable, and generally well-tolerated treatment for DME with retreatment every 6 months through at least 64 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04108156.
引用
- Khanani AM, Campochiaro PA, Graff JM, et al. Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema: The Pagoda Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40048197. doi:10.1001/jamaophthalmol.2025.0006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。